J7503 HCPCS Level II code: Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg

J7503 is the HCPCS code for “Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

J7503

Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg

Short description: Tacrol envarsus ex rel oral

HCPCS · United States

Medicare details

The indicators CMS publishes with J7503 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Special coverage instructions apply
Medicare pricing
Drugs
Type of service
Medical care; Immunosuppressive drugs
BETOS category
Other drugs
Added
Jan 1, 2016

Where J7503 sits

  1. 1J codesDrugs administered other than orally
  2. 2Active code J7503Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code J7503 mean?

J7503 is the HCPCS code for “Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover J7503?

CMS lists J7503’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.